Site Name: USA - Pennsylvania - Upper Providence, Switzerland - Zug, UK - London - Brentford, USA - Massachusetts - Waltham
Posted Date: Mar 14 2023

Vice President, Medicine Commercialization Leader, Oncology PD-1

Overview of GSK Commercial

By 2031, we aim to deliver more than £33 billion in annual sales – a step-change in performance and growth which will significantly increase the positive impact we can have on the health of billions of patients around the world. And we’re confident in our future.

2022 was a landmark year for GSK, delivering the step change in performance we committed to, driven by strong growth in specialty medicines and vaccines, including record sales for our shingles vaccine. We enter 2023 with strong momentum, underpinning confidence in our ambitious sales and profit outlooks for 2026.

At the same time, we continue to build a stronger portfolio and pipeline based on infectious diseases and the science of the immune system. Our innovative pipeline comprises 69 vaccines and specialty medicines, with 18 in phase III/registration.

We anticipate four approvals in 2023: Our potential best in class RSV vaccine for older adults (US, EU, JP); dostarlimab in first-line endometrial cancer (US); momelotinib in myelofibrosis (US) and daprodustat in chronic kidney disease (US, EU).

This momentum, together with further targeted business development, means GSK will also be in a strong position to deliver growth from 2026 onwards.

GSK’s portfolio spans three product areas: vaccines, specialty and general medicines and our focus is to deliver better and faster for patients globally. We’re prioritizing investment in vaccines and specialty medicines, which we expect to grow to around three quarters of our business in the next five years.

Our unrivalled vaccine portfolio targets infectious diseases at every stage of life, helping to reduce the burden of disease for hundreds of millions of people. GSK has exceptional capabilities in vaccine science and technologies, including adjuvant/protein and mRNA.

In specialty medicines, we are at the forefront of HIV prevention and treatment, and we are building our presence in key therapeutic areas such as oncology and immuno-inflammation.

General medicines include our inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases.

Every day, GSK medicines and vaccines protect and improve health, making life better for millions of people all over the world.

GSK in Oncology

GSK is committed to maximizing patient survival through transformational medicines. Our strategic approach to oncology research focuses on areas where we have the capabilities to make a difference:

• Immuno-oncology to harness the body’s immune system to fight cancer.
• Synthetic lethality to combine two genetic mechanisms to destroy cancerous cells.
• Tumor cell targeting to identify cancer cell-specific traits.

We have accelerated research areas including synthetic lethality and next generation immuno-oncology agents, drawing on our own expertise in human genetics and the science of the immune system, and that of our partners. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, and antibody-drug conjugates, either alone or in combination.

Dostalimab

Dostarlimab is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.

GSK’s ambition is for dostarlimab to become the backbone of the Company’s ongoing immuno-oncology-based research and development program, when used alone and in combination with standard-of-care and future novel cancer therapies, particularly in patients with currently limited treatment options. Dostarlimab is being investigated in registrational enabling trials as monotherapy and as part of combination regimens, including in women with recurrent or primary advanced endometrial cancer, women with Stage III or IV non-mucinous epithelial ovarian cancer, and patients with other advanced solid tumors or metastatic cancers.

In February 2023 the US FDA granted full approval for dostarlimab for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen and are not candidates for curative surgery or radiation

In the EU, dostarlimab is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.

in the US, dostarlimab is also indicated for patients with dMMR recurrent or advanced solid tumors, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.

A recent study of dostarlimab in first line endometrial cancer (RUBY) read out positive and full data will be presented at the upcoming medical meeting. With RUBY, dostarlimab will be a first anti-PD1 agent in first-line endometrial cancer.

In addition to the existing indications, dostarlimab had some unprecedented data for locally advanced rectal cancer presented at the 2022 ASCO meeting. Following these data, GSK’s oncology organization suggested a bold development plan to the FDA, and, based on the strength of the early data, the FDA ODAC recommended to support it.

Position summary – Medicine Commercialization Leader (MCL), PD-1

The Medicine Commercialization Leader (MCL) acts as the single point of global commercial leadership for a product (dostarlimab). Operating at the vice president level, (s)he leads a cross-functional global team and is accountable for investments and returns of the asset globally.

The MCL is responsible for developing and delivering the global medicine strategy, including the target profile, patient population and strategic launch plan for key markets, as well as the long-term lifecycle management plan, drawing upon significant commercial and strategic expertise.

The MCL and their counterpart in clinical development, the Medicine Development Leader (MDL), operate in a close partnership to jointly own, build and execute the development and commercialization strategy for the medicine.

Job Purpose

As a Global Product Strategy leader, the MCL leads the translation of our science into commercial success throughout the product lifecycle by ensuring we define long term strategic visions for our assets, drive competitive product profiles, and build long-term brand value, working in partnership with the cross functional medicine development team.

The MCL also manages the development of insight-driven global product strategies and plans, delivers ambitious long-range forecasts, enables outstanding launches, and ensures excellent customer experience in partnership with co-create markets through creating omnichannel content.

One key focus of the role is to develop and stretch oneself and the team to be best-in-industry at unlocking long term asset value.

Leadership team activities

The MCL chairs the dostarlimab Medicine Commercialization Team (MCT), comprising the MDL, Global Medical Affairs Lead (GMAL), Business Unit Heads from the key markets, and functional representatives from CMC, Supply Chain, Finance, Pricing & Market Access, Analytics & Intelligence, and Communications & Government Affairs.

This team is responsible for all global brand commercial activities to maximize asset value through the product lifecycle, from 3-6 months prior to commit-to-phase-3, through to loss of exclusivity.

The MCL is the single point of accountability for MCT activities to the global commercial leadership team (GCLT) and Pharma Investment Board (PIB). (S)he also sits on the Medicine Development Team (MDT) and regularly attends GSK’s Forecast Review Committee (FRC), Development Review Board (DRB) and PIB.

The MCL, PD-1/Dostarlimab reports to the SVP, Global Product Strategy, Oncology. It is a highly visible role with key stakeholders at the highest levels of GSK leadership.

Impact

The MCL will be expected to deliver significant impact at different levels and position GSK as a leader in the relevant therapy area sphere(s). As such, the incumbent will need to be able to articulate to the GSK Global Leadership Team (GLT) the investment needed to achieve the capabilities and numerical resources to be successful, as well as work closely with R&D to communicate the required studies to win, and with Pharmaceutical Supply Chain (PSC) to ensure the stability of the supply chain using multiple formulations.

Candidate Profile

Basic Qualifications

• Education: Bachelor’s degree or equivalent.
• Oncology experience: Industry commercial leadership experience in oncology.
• Commercial: Experience of Marketing/Commercial Strategy in a Pharma Commercial and Global R&D environment.
• Senior leadership: Experience at Senior Director level or above, including line and matrix management responsibility.
• Launch excellence: Experienced in both early and late-stage commercialization, progressing assets from pre-launch into the market.

Preferred Qualifications

• Education: Master’s degree/MBA/PhD strongly preferred.
• Immune-oncology: Knowledge and experience of immune-oncology.
• R&D: Understanding of the R&D process and risks, local affiliate operations and customer interface.
• Operational Leadership: Experience of managing a salesforce and P&L as a sales leader or business unit head.
• Cross-functional influencing: strong ability to work adeptly cross-functionally and influence across a matrix organization.
• People leadership: Excellent leadership/communication skills and a demonstrable influencer, challenger, and supporter of senior and multifunctional stakeholders.
• Enterprise leadership: Enterprise thinking with entrepreneurial flair for novel go-to-market model development.
• Stakeholder engagement: Demonstrated ability to engage with external thought leaders.
• Payer and HTA acumen: Strong Payer and HTA acumen.
• Strategic partnership: Experienced in strategic partnership/alliances.

Location

This global leadership position may be based at any of the GSK global commercial hub locations including Brentford, UK, Philadelphia PA, USA, Boston MA, USA, or Zug, Switzerland.

We will consider alternative locations on a case-by-case basis in line with our Performance with Choice principles.

GSK is a global biopharma company with a special purpose – to unite science, technology and talent to get ahead of disease together – so we can positively impact the health of billions of people and deliver stronger, more sustainable shareholder returns – as an organisation where people can thrive. Getting ahead means preventing disease as well as treating it, and we aim to impact the health of 2.5 billion people around the world in the next 10 years.

Our success absolutely depends on our people. While getting ahead of disease together is about our ambition for patients and shareholders, it’s also about making GSK a place where people can thrive. We want GSK to be a workplace where everyone can feel a sense of belonging and thrive as set out in our Equal and Inclusive Treatment of Employees policy. We’re committed to being more proactive at all levels so that our workforce reflects the communities we work and hire in, and our GSK leadership reflects our GSK workforce.

If you require an accommodation or other assistance to apply for a job at GSK, please contact the GSK Service Centre at 1-877-694-7547 (US Toll Free) or +1 801 567 5155 (outside US).

GSK is an Equal Opportunity Employer and, in the US, we adhere to Affirmative Action principles. This ensures that all qualified applicants will receive equal consideration for employment without regard to race, color, national origin, religion, sex, pregnancy, marital status, sexual orientation, gender identity/expression, age, disability, genetic information, military service, covered/protected veteran status or any other federal, state or local protected class.

At GSK, the health and safety of our employees are of paramount importance. As a science-led healthcare company on a mission to get ahead of disease together, we believe that supporting vaccination against COVID-19 is the single best thing we can do in the US to ensure the health and safety of our employees, complementary workers, workplaces, customers, consumers, communities, and the patients we serve.

GSK has made the decision to require all US employees to be fully vaccinated against COVID-19, where allowed by state or local law and where vaccine supply is readily available. The only exceptions to this requirement are employees who are approved for an accommodation for religious, medical or disability-related reasons.

Important notice to Employment businesses/ Agencies

GSK does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact GSK's commercial and general procurement/human resources department to obtain prior written authorization before referring any candidates to GSK. The obtaining of prior written authorization is a condition precedent to any agreement (verbal or written) between the employment business/ agency and GSK. In the absence of such written authorization being obtained any actions undertaken by the employment business/agency shall be deemed to have been performed without the consent or contractual agreement of GSK. GSK shall therefore not be liable for any fees arising from such actions or any fees arising from any referrals by employment businesses/agencies in respect of the vacancies posted on this site.

Please note that if you are a US Licensed Healthcare Professional or Healthcare Professional as defined by the laws of the state issuing your license, GSK may be required to capture and report expenses GSK incurs, on your behalf, in the event you are afforded an interview for employment. This capture of applicable transfers of value is necessary to ensure GSK’s compliance to all federal and state US Transparency requirements. For more information, please visit GSK’s Transparency Reporting For the Record site.